Key result
Sacubitril/valsartan reduces all-cause mortality ~10% and lowers readmissions vs ACEI or ARBs in heart failure.
Why the study?
Randomized trials showed sacubitril/valsartan lowers NT-proBNP compared to ACEI/ARBs, but results for CV mortality, HF rehospitalization, and all-cause mortality have been mixed.
Does sacubitril/valsartan reduce all-cause mortality, cardiovascular-related mortality, and heart failure rehospitalization in patients with heart failure compared to ACE inhibitors or ARBs?
Meta-Analysis (n=25,167)
Randomized
Yes
Does sacubitril/valsartan reduce all-cause mortality, cardiovascular-related mortality, and heart failure rehospitalization in patients with heart failure compared to ACE inhibitors or ARBs?
Sacubitril/valsartan significantly reduces heart failure rehospitalizations across all ejection fractions and lowers all-cause mortality specifically in patients with EF ≤40% when compared to ACE inhibitors or ARBs.
Answers are grounded in this paper and cite their sources.
Supports sacubitril/valsartan over ACEi/ARBs in HFrEF; confirms mortality benefit while extending readmission data across EF.
BACKGROUND: Sacubitril/valsartan (SAV) is crucial for managing heart failure (HF). Randomized clinical trials have shown SAV's superiority over angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) in reducing N-terminal pro-B-type natriuretic peptide levels. However, results for cardiovascular (CV) mortality, HF rehospitalization, and all-cause mortality have been mixed. OBJECTIVES: This study aimed to determine hard endpoints among the population with HF treated with SAV vs ACEI/ARBs and conduct a comprehensive risk-benefit analysis of the safety profile for SAV vs ACEI/ARB. METHODS: test was used to assess between-study heterogeneity. Publication bias was assessed via funnel plots and the Egger test. This study was registered in PROSPERO (CRD42024497661). RESULTS: The study included a total of 14 trials (n = 25,167). SAV reduced all-cause mortality in the population with an ejection fraction (EF) ≤40% (RR: 0.88; 95% CI: 0.81-0.94; P = 0.0006), but not in those with EF >40% (RR: 0.97; 95% 0.85-1.11; P = 0.67). There was no difference in CV mortality across EF spectrums (RR: 0.9; 95% CI: 0.79-1.03; P = 0.13). HF readmission was lower in the SAV-treated group regardless of EF (RR: 0.85; 95% CI: 0.79-0.91; P = 0.00001). CONCLUSIONS: The SAV-treated group, across all EF spectrum, was less likely to be rehospitalized than the ACEI/ARB-treated group. However, all-cause mortality reduction was only noted in the SAV group with EF <40%. No reduction in CV-related mortality was observed across the EF spectrum.
No takes yet. Share an insight, caveat, or question.
Evbayekha et al. (2025) conducted a meta-analysis in Heart failure (n=25,167). Sacubitril/Valsartan vs. ACE Inhibitors or ARBs was evaluated on All-cause mortality (RR 0.90, 95% CI 0.84-0.96, p=0.001). Sacubitril/valsartan reduced all-cause mortality and heart failure readmissions compared to ACE inhibitors or ARBs in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: